Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies
详细信息 查看全文
- 作者：Arlene D. Stark ; Shaun Jordan ; Kelly A. Allers ; Robert L. Bertekap ; Ruoyan Chen ; Tanaz Mistry Kannan ; Thaddeus F. Molski ; Frank D. Yocca ; Trevor Sharp and Tetsuro Kikuchi ; et al.
- 关键词：Aripiprazole ; Dopamine ; Serotonin ; Schizophrenia ; Partial agonist ; Antagonist
- 刊名：Psychopharmacology
- 出版年：2007
- 出版时间：February, 2007
- 年：2007
- 卷：190
- 期：3
- 页码：373-382
- 全文大小：275 KB
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology
Psychiatry - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-2072
文摘
Background Aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydro-2(1H)-quinolinone) is a novel antipsychotic with a mechanism of action that differs from current typical and atypical antipsychotics. Aripiprazole interacts with a range of receptors, including serotonin [5-hydroxytryptamine (5-HT)] and dopamine receptors.